HeartFlow vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
HeartFlow creates AI-powered, non-invasive 3D models of coronary arteries from CT scans to guide treatment of coronary artery disease, with FDA clearance and coverage from major insurers including Cigna.
About
HeartFlow, Inc. is a Redwood City, California–based medical technology company founded in 2011 that applies artificial intelligence to cardiac imaging to transform the diagnosis and management of coronary artery disease (CAD). Its flagship HeartFlow FFRCT Analysis generates a personalized, color-coded 3D model of a patient's coronary arteries from a standard CT scan, calculating fractional flow reserve values non-invasively to identify which blockages actually restrict blood flow. The technology is backed by more than 600 peer-reviewed publications and has helped clinicians manage over 400,000 patients worldwide.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.